Metabolic impacts of biguanides in type 2 diabetes therapy
DOI:
https://doi.org/10.5281/zenodo.19433766Keywords:
Biguanides, Metabolic effects, Cardiovascular effects, Type 2 diabetes, TreatmentAbstract
Introduction: Biguanides, especially metformin, are widely used in the treatment of type 2 diabetes mellitus (DM2) and are the first line of treatment for most patients. Objective: This study aims to investigate the metabolic and cardiovascular effects of biguanides, particularly metformin, in the treatment of type 2 diabetes mellitus. Methods: A systematic literature review was carried out of studies published between 2004 and 2024 in the PubMed, Web of Science, Scopus and Google Scholar databases. Original studies and reviews addressing the metabolic and cardiovascular effects of biguanides in the treatment of DM2 were included. Case reports, editorials, commentaries and studies focused on other medical conditions were excluded. Results and Discussion: Metformin improves insulin sensitivity, reduces hepatic glucose production and stabilizes or reduces body weight. In addition, it lowers the risk of cardiovascular events, improves the lipid profile, reduces systemic inflammation, improves endothelial function and may extend longevity. Studies indicate that metformin can also reduce the risk of certain types of cancer and improve the mental health of patients with DM2. Continuous treatment with metformin is associated with less progression of diabetic retinopathy. Conclusion: Metformin plays a crucial role in the treatment of DM2, offering benefits beyond glycemic control. The review highlights the importance of continuing to explore new agents derived from biguanides, with optimized safety and efficacy profiles, to further improve the management of DM2 and its complications.
References
ANFOSSI, Giovanni et al. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Current Vascular Pharmacology, v. 8, n. 3, p. 327-337, 2010.
APOSTOLOVA, Nadezda et al. Mechanisms of action of metformin in type 2 diabetes: Effects on mitochondria and leukocyte-endothelium interactions. Redox biology, v. 34, p. 101517, 2020.
BERSTEIN, Lev M. Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond. Future Oncology, v. 6, n. 8, p. 1313-1323, 2010.
CROWLEY, Matthew J. et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Annals of internal medicine, v. 166, n. 3, p. 191-200, 2017.
CONROY, Luke James et al. The Role of Nano-systems in the Delivery of Glucose-lowering Drugs for the Pre-emption and Treatment of Diabetes-associated Atherosclerosis. American Journal of Physiology-Cell Physiology, 2024.
DUAN, Meng et al. Sphingosine‐1‐phosphate in mitochondrial function and metabolic diseases. Obesity Reviews, v. 23, n. 6, p. e13426, 2022.
FORETZ, Marc et al. Metformin: from mechanisms of action to therapies. Cell metabolism, v. 20, n. 6, p. 953-966, 2014.
GRIFFIN, Simon J.; LEAVER, James K.; IRVING, Greg J. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia, v. 60, p. 1620-1629, 2017.
GEJL, Michael et al. Risk of cardiovascular disease: the effects of diabetes and anti-diabetic drugs—a nested case–control study. International Journal of Cardiology, v. 178, p. 292-296, 2015.
GIERISCH, Jennifer M. et al. Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: a systematic review and meta-analysis. The Journal of clinical psychiatry, v. 75, n. 5, p. 14280, 2014.
HOLMAN, Rury R. et al. 10-year follow-up of intensive glucose control in type 2 diabetes. New England journal of medicine, v. 359, n. 15, p. 1577-1589, 2008.
HERNANDEZ-BAIXAULI, Julia et al. Detection of early disease risk factors associated with metabolic syndrome: a new era with the NMR metabolomics assessment. Nutrients, v. 12, n. 3, p. 806, 2020.
INZUCCHI, Silvio E. et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, v. 58, p. 429-442, 2015.
LEON-GONZALEZ, Antonio J. et al. Role of metformin and other metabolic drugs in the prevention and therapy of endocrine-related cancers. Current Opinion in Pharmacology, v. 60, p. 17-26, 2021.
MONAMI, Matteo et al. Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease. International journal of cardiology, v. 126, n. 2, p. 247-251, 2008.
MATHU, R.; ABARNADEVIKA, A.; ARIHARASIVAKUMAR, G. A study of Biguanides in the Care of Type II DIABETES mellitus. J Pharm Sci Drug Discov, v. 1, n. 1, p. 1-9, 2021.
PERNICOVA, Ida; KORBONITS, Márta. Metformin—mode of action and clinical implications for diabetes and cancer. Nature Reviews Endocrinology, v. 10, n. 3, p. 143-156, 2014.
POLEDNICZEK, Michael et al. Micro-and Macrovascular Effects of Inflammation in Peripheral Artery Disease—Pathophysiology and Translational Therapeutic Approaches. Biomedicines, v. 11, n. 8, p. 2284, 2023.
PADHI, Santwana; NAYAK, Amit Kumar; BEHERA, Anindita. Type II diabetes mellitus: a review on recent drug based therapeutics. Biomedicine & Pharmacotherapy, v. 131, p. 110708, 2020.
RENA, Graham; HARDIE, D. Grahame; PEARSON, Ewan R. The mechanisms of action of metformin. Diabetologia, v. 60, n. 9, p. 1577-1585, 2017.
SHAHRAJABIAN, Mohamad H.; CHENG, Qi; SUN, Wenli. The importance of neglected and underutilized medicinal plants from South America in modern pharmaceutical sciences. Letters in Drug Design & Discovery, v. 20, n. 11, p. 1688-1706, 2023.
SAW, Mercy et al. New anti-hyperglycaemic agents for type 2 diabetes and their effects on diabetic retinopathy. Eye, v. 33, n. 12, p. 1842-1851, 2019.
TOP, Wiebe MC; KOOY, Adriaan; STEHOUWER, Coen DA. Metformin: a narrative review of its potential benefits for cardiovascular disease, cancer and dementia. Pharmaceuticals, v. 15, n. 3, p. 312, 2022.
TRIGGLE, Chris R. et al. Metformin: Is it a drug for all reasons and diseases?. Metabolism, v. 133, p. 155223, 2022.
TULIPANO, Giovanni. Integrated or independent actions of metformin in target tissues underlying its current use and new possible applications in the endocrine and metabolic disorder area. International journal of molecular sciences, v. 22, n. 23, p. 13068, 2021.
WU, Hao et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nature medicine, v. 23, n. 7, p. 850-858, 2017.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Journal of Social Issues and Health Sciences (JSIHS)
This work is licensed under a Creative Commons Attribution 4.0 International License.
